BioAtla Investor Presentation Deck

CAB-CTLA-4 (BA3071) Grade 3+ Adverse Events of Special Interest 7 mg (N=1) BA3071 Q3W + nivolumab 240 mg Q3W Number of subjects with at least one Grade 3+ AESI GI Toxicity Abdominal pain Diarrhea Liver Toxicity AST increased ALP increased Pulmonary Toxicity Pneumonia Endocrine Toxicity Diabetic ketoacidosis bicatla ^Patient with diarrhea also experienced Grade 3 gastritis * 1 Pt at 350 mg dose for Phase 2 included Red text denotes immune related AES 0 Data Cut Date: 15Nov23 AST - Aspartate aminotransferase; ALP - Alkaline phosphatase 0 0 0 0 0 0 0 21 mg (N=1) 0 0 0 0 0 0 0 0 Only 2 patients with immune related AEs observed among 18 treated patients 0 70 mg (N=3) 0 2 1 1 0 2 0 0 0 210 mg (N=3) 0 0 0 0 0 0 0 0 0 350 mg (N=7)* 1 0 1 0 1 0 0 0 0 700 mg (N=3) 2 0 0 0 0 0 0 1 1 1 1 Total (N=18) 5 (27.8) 2 (11.1) 1 (5.6) 1 (5.6) 2 (11.1) 1 (5.6) 2 (11.1) 1 (5.6) 1 (5.6) 1 (5.6) 1 (5.6) BioAtla| Overview 16

View entire presentation